Journal of Diabetes Investigation最新文献

{"title":"Circulating cell-free mitochondrial DNA in diabetes mellitus: Current insights and unexplored frontiers","authors":"Mohammadreza Akbari,&nbsp;Fatemeh Masjedi,&nbsp;Mohammad Nekooeian,&nbsp;Mahintaj Dara,&nbsp;Jamshid Roozbeh","doi":"10.1111/jdi.70071","DOIUrl":"10.1111/jdi.70071","url":null,"abstract":"<p>The role and significance of circulating cell-free mitochondrial DNA (ccf-mtDNA)—small fragments of mitochondrial DNA present in plasma—are becoming increasingly clear in various diseases. The release of mtDNA into the plasma results from mitochondrial dysfunction, cell death, and NETosis, all of which are elevated in diabetes and its complications. Due to its resemblance to pathogenic DNA, mitochondrial DNA can activate several immunological pathways, leading to inflammation—a key factor in diabetes and its complications. Studies reveal a significant overlap between the immunological pathways involved in diabetes and those triggered by ccf-mtDNA. Thus, ccf-mtDNA may play a crucial role in the pathophysiology of diabetes and its complications, making it a potential diagnostic, prognostic, and therapeutic target. This review aims to summarize research findings on the role of ccf-mtDNA in diabetes, including gestational diabetes and related complications. Most studies have focused on type 2 diabetes, whereas research on ccf-mtDNA in other forms, including type 1 diabetes, remains limited. By synthesizing these insights, we seek to clarify the role of ccf-mtDNA in diabetes and identify gaps for future research.</p>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 9","pages":"1575-1582"},"PeriodicalIF":3.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70071","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144273791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes and women's health","authors":"Ronald CW Ma,&nbsp;Edith WK Chow,&nbsp;Noel YH Ng,&nbsp;Takashi Sugiyama,&nbsp;Yuzhi Deng,&nbsp;Wing Hung Tam,&nbsp;So Ling Lau,&nbsp;Liona C Poon,&nbsp;Cuilin Zhang,&nbsp;Usha Sriram","doi":"10.1111/jdi.70095","DOIUrl":"10.1111/jdi.70095","url":null,"abstract":"<p>There is increasing interest in the implementation of precision medicine in diabetes. Gender is an important determinant of health, and there are numerous characteristics of diabetes in women that can be taken into account for the implementation of precision medicine in diabetes. Furthermore, better appreciation of the unique clinical characteristics of diabetes in women, especially in relation to the lifecourse perspective of a woman's life, would greatly enhance public health efforts to address diabetes and its associated risk factors, and to improve the lives of women and the next generation. These include the unique challenges and opportunities linked with polycystic ovary syndrome, gestational diabetes, other pregnancy complications including preeclampsia, and the potential impact of these diagnoses in the offspring of affected women. In this review article, we will summarize some of these key aspects of how diabetes intersects with women's health, and how a holistic, integrative, and lifecourse approach to diabetes and women's health can have a significant impact well beyond just the benefits of achieving better glucose control for the women living with diabetes, but more importantly, toward improved prevention and control of noncommunicable diseases on a population level.</p>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 7","pages":"1173-1190"},"PeriodicalIF":3.1,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70095","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144256923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"METTL3/YTHDF3 m6A axis promotes ferroptosis in diabetic kidney disease by stabilizing TfR1","authors":"Jinmei Zhang,&nbsp;Xiaoping Zhou,&nbsp;Bin Wang,&nbsp;Yan Yin,&nbsp;Daihao Wei,&nbsp;Kun Li","doi":"10.1111/jdi.70094","DOIUrl":"10.1111/jdi.70094","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Diabetic kidney disease (DKD) is a common complication of diabetes. N6-Methyladenosine (m⁶A) modification is a widely studied epigenetic mechanism. Methyltransferase-like (METTL) 3 is a well-studied methyltransferase. This study aimed to investigate the role of METTL3 in DKD and the underlying mechanism.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Thirty-five DKD patients and 28 control volunteers were recruited. Animal and cell DKD models were established. QRT-PCR and Western blot were performed to analyze the expression of METTL3 and fibrosis-related indicators. Cell viability and proliferation were assessed via a cell counting kit-8 and colony formation assays. Ferrous iron (Fe²⁺), malonaldehyde (MDA), and glutathione (GSH) contents were measured by commercial kits. The interaction between METTL3/YTH N6-methyladenosine RNA binding protein (YTHDF)3 and transferrin receptor-1 (TfR1) was examined through RNA immunoprecipitation and dual-luciferase reporter assays.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Results showed that METTL3-mediated m⁶A modification was elevated in kidney tissues of DKD patients and in high glucose (HG)-treated human renal mesangial cells (HRMCs). Besides, HG-treated HRMCs showed increased ferroptosis. In addition, METTL3 inhibition increased cell proliferation and inhibited ferroptosis in HRMCs. Mechanically, the METTL3/YTHDF3 m⁶A axis enhanced the stability of TfR1 mRNA. Moreover, YTHDF3 inhibition increased cell proliferation and inhibited ferroptosis in HRMCs. Finally, <i>in vivo</i> study results indicated that METTL3 deficiency inhibited ferroptosis and improved pathological damages.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In summary, METTL3/YTHDF3 m⁶A axis promoted ferroptosis in DKD by stabilizing TfR1, which could provide a reference for DKD treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 9","pages":"1610-1622"},"PeriodicalIF":3.0,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70094","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144256977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leptin promoter G2548A variant, elevated plasma leptin levels, and increased risk of Type 2 diabetes with CAD in Iranian patients: A genetic association study","authors":"Leila Saremi,&nbsp;Nazanin Ahmadi,&nbsp;Fatemeh Feizy,&nbsp;Shirin Lotfipanah,&nbsp;Mohammad Ebrahim Ghaffari,&nbsp;Zohreh Saltanatpour","doi":"10.1111/jdi.70077","DOIUrl":"10.1111/jdi.70077","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Type 2 diabetes mellitus (T2DM) is a significant risk factor for coronary artery disease (CAD). Leptin polymorphism is known to be associated with obesity and Type 2 diabetes mellitus. This study aimed to investigate the possible links between a specific leptin polymorphism (LEP 2548G/A) and plasma leptin level with the risk of Type 2 diabetes mellitus patients with CAD in the Iranian population for the first time.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>A total of 150 patients with Type 2 diabetes mellitus and CAD were included in the study, along with 150 nondiabetic controls. Blood samples were collected from participants. Biochemical analysis and genotyping were done using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The plasma leptin level was higher in females in the case group. There was a positive correlation between females and obese diabetic subjects (<i>P</i> &lt; 0.001). Regarding the single-nucleotide polymorphism in the leptin gene promoter, we found that the variant genotypes AA and GG were associated with a twofold (OR = 2.09, <i>P</i> = 0.006) and fourfold (OR = 4.2, <i>P</i> = 0.017) increased risk of Type 2 diabetes mellitus patients with CAD, respectively. The GG genotype was also associated with obesity and higher plasma leptin level in the case group (OR = 4.92, <i>P</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Leptin G2548A and plasma leptin levels may contribute to Type 2 diabetes with CAD in the Iranian population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 9","pages":"1645-1652"},"PeriodicalIF":3.0,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70077","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144256924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood glucose screening in dental clinics as an opportunity for detection of diabetes and prediabetes: The Kyoutou Dental and Diabetes (KDD) Study","authors":"Nozomi Harai,&nbsp;Masato Tawata,&nbsp;Hiroyuki Nakamura,&nbsp;Takahito Fujitani,&nbsp;Shinji Akiyama,&nbsp;Tomoyuki Takagi,&nbsp;Kazuki Itsumura,&nbsp;Eri Shukuzawa,&nbsp;Syuuichi Saotome,&nbsp;Jin Mikami,&nbsp;Akira Ozawa,&nbsp;Kouki Oka,&nbsp;Kenji Mitsuzuka,&nbsp;Ai Isoyama,&nbsp;Minoru Nakazato,&nbsp;Eizou Okubo,&nbsp;Norihiko Yokomori,&nbsp;Kaoru Aida,&nbsp;Tadao Ooka,&nbsp;Kyoichiro Tsuchiya","doi":"10.1111/jdi.70093","DOIUrl":"10.1111/jdi.70093","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims/Introduction</h3>\u0000 \u0000 <p>This study aimed to determine the prevalence and characteristics of positive blood glucose screening for diabetes or prediabetes among dental patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>This prospective cohort study recruited 749 dental patients aged 18 years and older from October 1, 2023 to August 9, 2024. Patients undergoing treatment for diabetes were excluded. Blood glucose measurements were taken using fingerstick, with screening positivity defined as fasting blood glucose levels of 100 mg/dL or more or non-fasting blood glucose levels of 140 mg/dL or more. Positive individuals were referred to internal medicine clinics. The background and dental results of the positive and negative screening groups were compared, and multivariate logistic regression was performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Participants' average age was 54.5 ± 16.2 years, with 369 men (49.2%) and 19 women (2.5%) with a history of diabetes. Blood glucose screening was positive in 139 individuals (18.6%). Among the 34 patients who visited the internal medicine clinics, eight were diagnosed with diabetes and 10 with prediabetes. Patients in the positive group were significantly older, included more men, had more individuals with a history of diabetes, and exhibited a higher bleeding on probing (BOP) rate and alveolar bone loss (BL). The BOP rate and BL remained significant after adjustment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Blood glucose measurements in dental clinics may provide a practical and valuable opportunity for the early detection and intervention of diabetes and prediabetes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 9","pages":"1742-1749"},"PeriodicalIF":3.0,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70093","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144232786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tracing the molecular landscape of diabetic nephropathy: Insights from machine learning and experiment verification","authors":"Shahad W. Kattan,&nbsp;Ahmed M. Basri,&nbsp;Mohammad H. Alhashmi,&nbsp;Amany I. Almars,&nbsp;Reem Hasaballah Alhasani,&nbsp;Ifat Alsharif,&nbsp;Ikhlas A. Sindi,&nbsp;Ahmad H. Mufti,&nbsp;Iman S. Abumansour,&nbsp;Nasser A. Elhawary,&nbsp;Aishah Abdullah Qahtani,&nbsp;Hailah M. Almohaimeed","doi":"10.1111/jdi.70026","DOIUrl":"10.1111/jdi.70026","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Diabetes is a chronic disease resulting from insufficient insulin secretion or impaired insulin function. Diabetic nephropathy (DN) is one of the most common complications of diabetes and a leading cause of end-stage renal disease. Early diagnosis of DN is crucial for timely intervention and effective disease management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Gene expression profiles GSE142025 and GSE220226 were retrieved from the GEO database and combined into a metadata cohort, while GSE189007 was obtained as an independent validation dataset. Differentially expressed genes (DEGs) were identified in 46 glomerular samples from DN patients and 31 control samples. Gene Ontology (GO) and Disease Ontology (DO) enrichment analyses, gene set enrichment analysis (GSEA), least absolute shrinkage and selection operator (LASSO) regression, support vector machine-recursive feature elimination (SVM-RFE) analysis, and area under the curve (AUC) calculations were performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 109 DEGs were identified. Among them, <i>DUSP1</i>, <i>EGR1</i>, <i>FPR1</i>, <i>G6PC</i>, <i>GDF15</i>, <i>LOX</i>, <i>LPL</i>, <i>PRKAR2B</i>, <i>PTGDS</i>, and <i>TPPP3</i> were selected as potential diagnostic biomarkers for DN. These biomarkers exhibited a positive correlation with immune cell infiltration. Experimental validation identified <i>LOX</i> as the most promising novel diagnostic biomarker for DN. This study provides new insights into the early diagnosis, pathogenesis, and molecular mechanisms of DN.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 8","pages":"1473-1486"},"PeriodicalIF":3.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70026","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144223858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic analysis of the correlation between GLP1 action and metabolic liver disease: Insights from Mendelian randomization analysis","authors":"Zhiqiang Ma,&nbsp;Binyu Wang,&nbsp;Danpei Li,&nbsp;Xi Chen","doi":"10.1111/jdi.70087","DOIUrl":"10.1111/jdi.70087","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>Previous studies have shown that glucagon-like peptide 1 (GLP1) receptor agonists may help improve metabolic dysfunction-associated steatotic liver disease (MASLD), but supportive genetic data remain limited. Our study aims to explore the correlation between GLP1 action and MASLD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Mendelian randomization (MR) was performed, with 22 cis-eQTLs and 2 missense mutations used as proxies for GLP1 action. MASLD data from the FinnGen study served as the primary analysis, with replication in an independent cohort. Subsequently, mediation analyses were conducted to explore the role of MASLD risk factors in the correlation between GLP1 action and MASLD. Finally, phenome-wide association studies (Phe-WAS) were performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Using cis-eQTLs as exposure, genetically predicted GLP1 action was associated with a decreased risk of MASLD in the primary analysis [IVW: odds ratio (OR): 0.36; 95% confidence interval (CI): 0.30–0.44; <i>P</i> = 1.37E-22] and in the replication study (IVW: OR: 0.61; 95% CI: 0.47–0.81; <i>P</i> = 5.58E-04). In mediation analyses, the proportion of the mediation effect of GLP1 action via type 2 diabetes was 6% (95% CI: 0.0004–0.1138; <i>P</i> = 4.70E-02), via hypertension was 4% (95% CI: 0.0128–0.0675; <i>P</i> = 3.82E-03), while via high-density lipoprotein cholesterol was 1% (95% CI: 0.0039–0.0187; <i>P</i> = 2.52E-03). Using missense mutations as exposure, no causal relationship between GLP1 action and MASLD was observed. Phe-WAS showed cardiovascular and renal benefits of GLP1 action.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our genetic analysis suggests a possible causal relationship between GLP1 action and MASLD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 8","pages":"1409-1419"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70087","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144197781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep habits in the pathogenesis and management of diabesity","authors":"Cecilie Holm Rasmussen,&nbsp;Chun Kwan O,&nbsp;Wai Sze Chan,&nbsp;Faidon Magkos,&nbsp;Alice PS Kong","doi":"10.1111/jdi.70075","DOIUrl":"10.1111/jdi.70075","url":null,"abstract":"<p>In parallel with the rising global epidemic of obesity and diabetes, termed “diabesity” to underscore the strong relationship between these two conditions, there has been a decreasing trend in the average sleep duration in many parts of the world. Sleep is an essential component of everyday life and plays a pivotal role in regulating energy metabolism and many other physiological functions. Updated guidelines include adequate sleep as one of the key elements of lifestyle therapy in diabetes management. From epidemiological studies, there are many researchers across the globe demonstrating a U-shaped relationship between sleep duration and glycemia, as well as more adverse clinical outcomes (notably cardiovascular events and mortality) with shorter sleep in people with diabetes. Sleep deprivation results in inflammation, neurohormonal dysregulation impacting on appetite control, hedonic pathways, and reward processing and eventually facilitates obesity and diabetes. While there is a wealth of evidence supporting the mechanistic links between short sleep duration, weight gain, and dysglycemia, the reasons why long sleepers have worse metabolic health remain obscure. Not only sleep duration matters, but circadian alignment and quality of sleep are also crucial in optimizing metabolic health. Recognizing the importance of promoting sleep hygiene via non-pharmacological strategies, such as sleep extension interventions and cognitive behavioral therapy, is attracting increasing clinical attention to prevent and manage people with diabesity.</p>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 7","pages":"1202-1216"},"PeriodicalIF":3.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70075","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144197794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenotypic characteristics of diabetic neuropathic pain and factors associated in patients with Diabetes Mellitus-type 2","authors":"Helena De Sola,&nbsp;María Dueñas,&nbsp;Inmaculada Failde,&nbsp;Jenifer Palomo-Osuna,&nbsp;Cristina Naranjo,&nbsp;Alejandro Salazar","doi":"10.1111/jdi.70089","DOIUrl":"10.1111/jdi.70089","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims/Introduction</h3>\u0000 \u0000 <p>To identify subgroups of patients with diabetic neuropathic pain according to their phenotypic characteristics and factors associated with belonging to each of these groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>A multicenter cross-sectional study carried out in patients with DM-type2 and diabetic neuropathy. We recorded sociodemographic and clinical data, intensity of pain, pain phenotypes, mood disorders, sleep quality, social support, and health-related quality of life. A hierarchical cluster analysis was carried out to find groups according to their phenotype. The factors associated with belonging to these groups were assessed with a multinomial logistic regression model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Four phenotypic groups were found: G1 with longer pain duration, predominance of pain provoked by brushing or pressure, and sensation of pins/needles and tingling; G2 characterized by stabbing, pins and needles, and electric shocks; G3 with lower scores in all the NPSI items; and G4 with low-moderate scores in almost all the items, but showing some level of pins and needles and tingling. Intensity and duration of pain, and level of anxiety were the factors associated with belonging to G1, G2, and G4 with respect to G3, although the magnitude of the risk was slightly different among them.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Specific treatment strategies should be developed for the different profiles found, with special attention to those with more pain and anxiety levels, including cognitive-behavioral therapies or mindfulness-based interventions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 8","pages":"1495-1506"},"PeriodicalIF":3.0,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70089","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suboptimal physician adherence to evidence-based guidelines for managing cardiorenal comorbidities in diabetes care: A retrospective single-center study in Taiwan","authors":"Zong-Yu Shen,&nbsp;Horng-Yih Ou","doi":"10.1111/jdi.70090","DOIUrl":"10.1111/jdi.70090","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>In patients with diabetes and cardiorenal comorbidities, sodium–glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are critical to secondary outcome prevention. This study investigated physicians' adherence to current cardiorenal-diabetic prescription guidelines for such patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>This observational, retrospective-cohort, single-center study enrolled 7,805 adults (mean age 71 years; mean HbA1c level 7.4%) with type 2 diabetes mellitus and atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), or chronic kidney disease (CKD). Patients' demographic information, comorbidities, medication history, and laboratory data were collected. Physician adherence was defined as a patient with ASCVD receiving an SGLT2i or GLP-1 RA and a patient with CKD or HF receiving an SGLT2i. The baseline characteristics of the adherence and nonadherence groups were compared.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Only 28.4% of prescriptions adhered to guidelines. Patients in the physician-adherent group had higher HbA1c levels, body mass index, and age, and more comorbidities. Logistic regression revealed that older age [odds ratio (OR) 2.29, 95% confidence interval (CI) 2.014–2.604, <i>P</i> &lt; 0.001], cerebrovascular accident history (OR 1.591, 95% CI 1.357–1.865, <i>P</i> &lt; 0.001), and dipeptidyl peptidase 4 inhibitor use (OR 2.359, 95% CI 2.062–2.700, <i>P</i> &lt; 0.001) were associated with physician nonadherence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Only a suboptimal percentage of patients with diabetes and cardiorenal disease in Taiwan receive SGLT2is and GLP-1 RAs despite these medications' recognized cardiorenal benefits. Further action is required to improve physician adherence in patients with greater age, cerebrovascular accident history, and dipeptidyl peptidase 4 inhibitor use.</p>\u0000 </section>\u0000 </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 8","pages":"1535-1542"},"PeriodicalIF":3.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70090","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}